HistoIndex expands AI-based digital pathology platform

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Jezperklauzen)
(Image: Getty/Jezperklauzen)

Related tags: Pathology, Drug discovery, Preclinical contract research

The Singapore-based company recently expanded its AI-based digital pathology platform to support preclinical discovery and drug development programs.

HistoIndex’s Second Harmonic Generation (SHG) technology is a stain-free method quantifies more than 450 parameters associated with nonalcoholic steatohepatitis (NASH), including fibrosis, inflammation, ballooning, and steatosis, according to the company.

"While there are no US Food and Drug Administration (FDA) approved drugs today, there are currently multiple clinical trials to find a treatment for NASH,” ​said Dr. Gideon Ho, chief commercial officer, HistoIndex.

“Therefore, there is an urgent need to monitor therapeutic responses for positive outcomes in drug discovery, one of which is quantifying changes in NASH characteristics such as fibrosis, steatosis, lobular inflammation, and hepatocyte ballooning,”​ he told us.

“Here is where innovative technologies like HistoIndex's AI-based digital pathology platform can support pharmas and biotechs in their preclinical discovery as well as drug development program for NASH."

HistoIndex partners with pharma and biotech, contract research organizations (CROs), academia, and other research institutes, and is currently involved in multiple preclinical studies in addition to several ongoing NASH trials.

The company recently inked a collaboration with the A*STAR's Genome Institute of Singapore (GIS) to validate in vivo​ and in vitro​ NASH models. It also is providing R&D services and smart imaging analysis to the CRO, WuXi Apptec.

Related news

Related products

show more

Validating The Simoa Technology

Validating The Simoa Technology

Frontage Laboratories | 01-Oct-2019 | Technical / White Paper

Frontage is the first and only laboratory to validate Quanterix’ Simoa HD1 Analyzer for performing immunoassays. Most of the advanced instruments used...

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars